-
Product Insights
New![]()
Dungowan PHES
Dungowan PHES is a Hydro project located in New South Wales, Australia. The project is owned by Energy Estate Pty Ltd; Miruswind Pty Ltd; Walcha Energy and is developed by Energy Estate Pty Ltd; GE Renewable Energy; Miruswind Pty Ltd; Walcha Energy. The project is currently under construction. Empower your strategies with our Dungowan PHES report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within...
-
Product Insights
New![]()
Middleback Ranges PHES
Middleback Ranges PHES is a Hydro project located in South Australia, Australia. The project is owned by GFG Alliance Ltd; SIMEC Energy Australia Pty Ltd and is developed by GFG Alliance Ltd. The project is expected to come online in 2027. Empower your strategies with our Middleback Ranges PHES report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PHE-885 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHE-885 in Relapsed Multiple Myeloma Drug Details:PHE-885 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PHE-885 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHE-885 in Refractory Multiple Myeloma Drug Details:PHE-885 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADS-051 in Ulcerative Colitis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADS-051 in Ulcerative Colitis Drug Details: BT-051 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATRN-119 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATRN-119 in Colon Cancer Drug Details: ATRN-119 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MN-08 in Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. MN-08 in Alzheimer's Disease Drug Details: MN-08 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NZV-930 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NZV-930 in Pancreatic Ductal AdenocarcinomaDrug Details:NZV-930 is under development for the treatment of solid tumors, advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986249 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986249 in Triple-Negative Breast Cancer (TNBC) Drug Details: BMS-986249 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elenagen in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elenagen in Kidney Cancer (Renal Cell Cancer) Drug Details: Elenagen is under development for the...
-
Product Insights
![]()
Merakes Field, Indonesia
Merakes upstream field is located in Makassar Strait, Indonesia. The upstream field is owned by Eni East Sepinggan Ltd (65%); Neptune Energy East Sepinggan BV (20%); PT PHE East Sepinggan (15%). It is operated by Eni East Sepinggan Ltd. The project started its operations in 2021. Merakes Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production,...
-
Product Insights
![]()
Merakes East Upstream Project , Indonesia
Merakes East upstream project is located in Makassar Strait, Indonesia. The upstream project is owned by Eni East Sepinggan Ltd (65%); Neptune Energy East Sepinggan BV (20%); PT PHE East Sepinggan (15%). It will be operated by Eni East Sepinggan Ltd. The project is currently in the announced stage and is expected to start operations in 2025. Merakes East Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – PHE-885
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PHE-885 Drug Details PHE-885 is under development for the treatment of relapsed and refractory...
-
Sector Analysis
![]()
Peru Baby Food Market Size by Categories, Distribution Channel, Market Share and Forecast, 2022-2027
Peru Baby Food Market Report Overview The Peru baby food market size was valued at PEH877.1 million ($226 million) in 2021 and is expected to achieve a CAGR of less than 2% during 2021-2027. Baby milks dominated the Peruvian baby food sector and Nestlé remained the overall market leader in 2021. The Peru baby food market research report provides extensive and highly detailed current and future market trends in the Peru market. Peru Baby Food Market Outlook For more insights on...
-
Product Insights
![]()
Net Present Value Model: Kuvan
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Kuvan Drug Details Sapropterin dihydrochloride (Kuvan)...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADS-051
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ADS-051 Drug Details BT-051 is under development for the treatment of ulcerative colitis. The...
-
Product Insights
![]()
Clinical Chemistry Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
The clinical chemistry segment comprises reagents, test kits, and electrodes. This aid in determining the concentration or activity of biomolecules, such as proteins, carbohydrates, lipids, enzymes, minerals, or other small molecules. These biomolecules could be easily collected via body fluids such as blood, serum or plasma, and urine. The clinical chemistry pipeline market research report provides comprehensive information about the clinical chemistry pipeline products with a comparative analysis of the products at various stages of development and information about the...
-
Product Insights
![]()
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine. Tyrosine is used to make several types of hormones, certain chemicals that transmit signals in the brain (neurotransmitters), and a pigment called melanin, which gives hair and skin their color. The Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) Development market research report provides an in-depth analysis of Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.